Publicaciones en colaboración con investigadores/as de University of Paris-Saclay (19)

2023

  1. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

2020

  1. Combinatorial nanomedicine made of squalenoyl-gemcitabine and edelfosine for the treatment of osteosarcoma

    Cancers, Vol. 12, Núm. 7, pp. 1-13

  2. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  3. GLI1/GLI2 functional interplay is required to control Hedgehog/GLI targets gene expression

    Biochemical Journal, Vol. 477, Núm. 17, pp. 3131-3145

  4. Repurposing infectious disease vaccines for intratumoral immunotherapy

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  5. The importance of naturally attenuated SARS-CoV-2in the fight against COVID-19

    Environmental Microbiology, Vol. 22, Núm. 6, pp. 1997-2000

2019

  1. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process

    BMC Cancer, Vol. 19, Núm. 1

  2. Preclinical Evaluation of a Cell-Based Gene Therapy Using the Sleeping Beauty Transposon System in Choroidal Neovascularization

    Molecular Therapy - Methods and Clinical Development, Vol. 15, pp. 403-417

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

2017

  1. Predictors of responses to immune checkpoint blockade in advanced melanoma

    Nature Communications, Vol. 8, Núm. 1

  2. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

2014

  1. A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system

    Cellular and Molecular Life Sciences, Vol. 71, Núm. 23, pp. 4637-4651

  2. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

  3. Targeting VEGFR1 on endothelial progenitors modulates their differentiation potential

    Angiogenesis, Vol. 17, Núm. 3, pp. 603-616

2013

  1. Zinc chelation: A metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance

    Cell Death and Disease, Vol. 4, Núm. 10

2011

  1. Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy

    Journal of Experimental Medicine, Vol. 208, Núm. 3, pp. 491-503

2010

  1. In vivo depletion of T lymphocyte-specific transcription factors by RNA interference

    Cell Cycle, Vol. 9, Núm. 14, pp. 2902-2907

2007

  1. Calreticulin exposure dictates the immunogenicity of cancer cell death

    Nature Medicine, Vol. 13, Núm. 1, pp. 54-61